Business
Ascletis Presented Results from Cohorts 1 and 2 of 28-day Multiple Ascending Dose Study of Its Oral Small Molecule GLP-1R Agonist ASC30 at the 61st European Association for the Study of Diabetes (EASD) Annual Meeting
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that results from cohorts 1 and 2 of 28-day multiple ascending dose (MAD) study of its oral small molecule GLP-1 receptor (GLP-1R) agonist ASC30 (NCT06680440) were presented in the short oral discussion session event A at the 61st European Association for the Study of Diabetes (EASD) Annual Meeting in Vienna, Austria on September 16, 2025.
About this update from Ascletis Pharma, Inc.
[{"type":"text","content":"- ASC30 once-daily oral tablet demonstrated up to 6.5% placebo-adjusted mean body weight reduction from baseline after 28-day treatment. ","length":136,"tagName":"p"},{"type":"text","content":"- ASC30 tablet's higher efficacy is supported by its higher oral drug exposures.","length":84,"tagName":"p"},{"type":"text","content":"- ASC30 is safe and well tolerated with only mild-to-moderate gastrointestinal (GI) adverse events (AEs). There was no vomiting incidence in multiple ascending dose (MAD) cohort 1 due to 2 mg to 5 mg weekly titration strategy.","length":226,"tagName":"p"},{"type":"text","content":"HONG KONG, Sept. 16, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that results from cohorts 1 and 2 of 28-day multiple ascending dose (MAD) study of its oral small molecule GLP-1 receptor (GLP-1R) agonist ASC30 (NCT06680440) were presented in the short oral discussion session event A at the 61st European Association for the Study of Diabetes (EASD) Annual Meeting in Vienna, Austria on September 16, 2025.","length":449,"tagName":"p"},{"type":"text","content":"The Phase Ib MAD study is a randomized, double-blind, placebo-controlled study, conducted in the U.S., to evaluate safety and tolerability, various titration schemes, pharmacokinetics (PK) and preliminary efficacy of ASC30 once-daily oral tablet in participants with obesity (body mass index (BMI): 30-40 kg/m2).","length":312,"tagName":"p"},{"type":"text","content":"ASC30 once-daily oral tablet demonstrated a 6.5% placebo-adjusted mean body weight reduction from baseline after 28-day treatment in MAD cohort 2 (weekly titrations of 2 mg, 10 mg, 20 mg, and 40 mg). ASC30 once-daily oral tablet also demonstrated a 4.5% placebo-adjusted mean body weight reduction from baseline after 28-day treatment in MAD cohort 1 (weekly titrations of 2 mg, 5 mg, 10 mg, and 20 mg). No sign of plateau was observed at Day 29.","length":446,"tagName":"p"},{"type":"text","content":"20 mg and 40 mg ASC30 demonstrated superior oral PK profile at steady state. Higher area under the curve (AUC) positively correlated with greater body weight reduction. Table 1 summarizes the PK profile of ASC30.","length":212,"tagName":"p"},{"type":"text","content":"Table 1. PK profile of ASC30","length":28,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"cols...